T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Abroad (travel likely)Recruiting

Conditions

Malignant Glioma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Iowa Health Care, Iowa City, Iowa, United States
Contact: Study coordinator (John Buatti, MD) · john-buatti@uiowa.edu · 319-356-7590
Contact: Study coordinator (John Buatti, MD) · john-buatti@uiowa.edu · (319) 356-7590

Study leads

John Buatti, MD
Principal Investigator
University of Iowa

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Anaplastic Oligodendroglioma · Astrocytoma, IDH-Mutant, Grade 3 · Astrocytoma, IDH-Mutant, Grade 4

Abroad (travel likely)RecruitingPHASE1, PHASE2

Rochester, United States

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

Malignant Glioma

Abroad (travel likely)Recruiting

Houston, United States

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Recurrent Glioblastoma · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Relapsed Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

IDH1 wt Allele · Recurrent Anaplastic Astrocytoma · Recurrent Glioblastoma

Abroad (travel likely)RecruitingPHASE1

Houston, United States